Advocacy intelligence hub — real-time data for patient organizations
University of Sao Paulo General Hospital — NA
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
XARELTO
(RIVAROXABAN)standardJanssen Pharmaceuticals, Inc.
Factor Xa Inhibitor [EPC]
12.1 Mechanism of Action XARELTO is a selective inhibitor of FXa. It does not require a cofactor (such as Anti-thrombin III) for activity. Rivaroxaban...